स्वीडन - स्वीडिश - Läkemedelsverket (Medical Products Agency)

viatris limited - apixaban - filmdragerad tablett - 5 mg - laktosmonohydrat hjälpämne; natriumlaurilsulfat hjälpämne; apixaban 5 mg aktiv substans; laktos (vattenfri) hjälpämne

स्वीडन - स्वीडिश - Läkemedelsverket (Medical Products Agency)

viatris limited - apixaban - filmdragerad tablett - 2,5 mg - natriumlaurilsulfat hjälpämne; laktosmonohydrat hjälpämne; laktos (vattenfri) hjälpämne; apixaban 2,5 mg aktiv substans

यूरोपीय संघ - स्वीडिश - EMA (European Medicines Agency)

mylan ire healthcare limited - bevacizumab - colorectal neoplasms; breast neoplasms; ovarian neoplasms; fallopian tube neoplasms; peritoneal neoplasms; carcinoma, non-small-cell lung; carcinoma, renal cell; uterine cervical neoplasms - antineoplastiska medel - treatment of carcinoma of the colon or rectum, breast cancer, non-small cell lung cancer, renal cell cancer, epithelial ovarian, fallopian tube or primary peritoneal cancer, and carcinoma of the cervix.

यूरोपीय संघ - स्वीडिश - EMA (European Medicines Agency)

mylan ireland limited - sitagliptin hydrochloride monohydrate, metformin hydrochloride - diabetes mellitus, typ 2 - läkemedel som används vid diabetes - for adult patients with type 2 diabetes mellitus:sitagliptin/metformin hydrochloride mylan is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. sitagliptin/metformin hydrochloride mylan is indicated in combination with a sulphonylurea (i. - , trippel kombinationsterapi) som ett komplement till kost och motion hos patienter bristfälligt kontrollerad på deras maximal tolererad dos av metformin och en sulphonylurea. sitagliptin/metformin hydrochloride mylan is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparg) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparg agonist. sitagliptin/metformin hydrochloride mylan is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.

यूरोपीय संघ - स्वीडिश - EMA (European Medicines Agency)

viatris limited - aflibercept - macular edema; retinal vein occlusion; diabetic retinopathy; myopia, degenerative; diabetes complications - ögonsjukdomar - yesafili is indicated for adults for the treatment ofneovascular (wet) age-related macular degeneration (amd) (see section 5. 1),visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo) (see section 5. 1),visual impairment due to diabetic macular oedema (dme) (see section 5. 1),visual impairment due to myopic choroidal neovascularisation (myopic cnv) (see section 5.

स्वीडन - स्वीडिश - Läkemedelsverket (Medical Products Agency)

alternova a/s - paracetamol - filmdragerad tablett - 1 g - paracetamol 1000 mg aktiv substans - paracetamol

स्वीडन - स्वीडिश - Läkemedelsverket (Medical Products Agency)

stasisport pharma - paracetamol - filmdragerad tablett - 1 g - paracetamol 1000 mg aktiv substans - paracetamol

स्वीडन - स्वीडिश - Läkemedelsverket (Medical Products Agency)

alternova a/s - paracetamol - filmdragerad tablett - 500 mg - paracetamol 500 mg aktiv substans - paracetamol

स्वीडन - स्वीडिश - Läkemedelsverket (Medical Products Agency)

evolan pharma ab - paracetamol - filmdragerad tablett - 500 mg - paracetamol 500 mg aktiv substans - paracetamol

स्वीडन - स्वीडिश - Läkemedelsverket (Medical Products Agency)

stasisport pharma - paracetamol - filmdragerad tablett - 500 mg - paracetamol 500 mg aktiv substans - paracetamol